De Novo device
EndeavorRx
Akili Interactive Labs, Inc. · Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder (QFT, Class II) · First FDA decision Jun 15, 2020, newest Dec 13, 2023ADHD
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
6
Naming "EndeavorRx"
MAUDE reports
1
Brand "EndeavorRx", since 2015
PubMed studies
15
Mentioning "EndeavorRx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EndeavorRx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- EndeavorRx510(k)
K231337 · Decided Dec 13, 2023 · 219 days after receipt
Device type: Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder (QFT) · Obstetrics & Gynecology
- EndeavorRxNew device typeDe Novo
DEN200026 · Decided Jun 15, 2020 · 60 days after receipt
Device type: Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder (QFT) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EndeavorRx", any status and sponsor, newest update first.
University of MichiganAcademic, hospital or other
NCT05697627 · 31 participants · Start May 3, 2023 · Primary completion Jul 1, 2024
Device: Computerized cognitive training (CCT) using EndeavorRx · For: Depression; Subclinical Depressive Symptoms
Sites: Ann Arbor, Michigan
Children's National Research InstituteAcademic, hospital or other
NCT05099874 · 20 participants (planned) · Start Dec 20, 2022 · Primary completion Dec 2025
Device: EndeavorRx · For: Sickle Cell Disease; Attention Deficit; Cognitive Deficit in Attention
Sites: Washington D.C., District of Columbia
Children's National Research InstituteAcademic, hospital or other
NCT05528939 · 50 participants (planned) · Start Jun 14, 2023 · Primary completion Aug 31, 2025
Device: EndeavorRx · For: Pediatric Cancer; Pediatric ALL; Pediatric Brain Tumor and 2 more
Sites: Washington D.C., District of Columbia
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EndeavorRx", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code QFT
2 reports: 2 malfunction, 0 injury, 0 death
Newest reports for this brand
- ENDEAVORRXMalfunction
MW5147655 · Received Nov 1, 2023
Device type: Digital Therapeutic Software For Attention Deficit Hyperactivity Disorder (QFT)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EndeavorRx"[tiab]. The summary above synthesizes these.
- Effects of game-based digital therapeutics on attention deficit hyperactivity disorder in children and adolescents as assessed by parents or teachers: a systematic review and meta-analysis.
Oh S, Choi J, Han DH, et al. · Eur Child Adolesc Psychiatry · 2024Meta-Analysis, Systematic Review
- New frontiers in pharmacological treatment of attention-deficit hyperactivity disorder.
Noah AA, Sedky HE · Naunyn Schmiedebergs Arch Pharmacol · 2025Review, Research Support, Non-U.S. Gov't
- Sentiment and Thematic Analysis of User Reviews for FDA-Cleared Prescription Digital Therapeutics: A Mixed-Methods Real-World Evidence Study.
Lakhan SE · Cureus · 2025
- Analyzing metaverse-based digital therapies, their effectiveness, and potential risks in mental healthcare.
Buragohain D, Khichar S, Deng C, et al. · Sci Rep · 2025Systematic Review
- Digital health interventions (DHI) for the treatment of attention deficit hyperactivity disorder (ADHD) in children - a comparative review of literature among various treatment and DHI.
Pandian GSB, Jain A, Raza Q, et al. · Psychiatry Res · 2021Review
- A data-centric artificial intelligent and extended reality technology in smart healthcare systems.
Shaikh TA, Dar TR, Sofi S · Soc Netw Anal Min · 2022Review
- A Single-Arm Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention for Attention, in Adults Diagnosed with Attention Deficit Hyperactivity Disorder.
Maple AM, Savarese A, Stamatis CA, et al. · CNS Spectr · 2024
- [Digital Therapy for ADHD: Endeavor Ride and the Current Status and Prospects of Next-Generation Therapeutic Apps].
Nishino R, Mikami K · Brain Nerve · 2025Review, English Abstract
- Decoding FDA Labeling of Prescription Digital Therapeutics: A Cross-Sectional Regulatory Study.
Lakhan SE · Cureus · 2025
- Postmarket Safety Surveillance of FDA-Cleared Prescription Digital Therapeutics Using the Manufacturer and User Facility Device Experience (MAUDE) Database: A Pharmacovigilance Study.
Lakhan SE · Cureus · 2025
- Sex Differences in Attention Improvements Across Two Clinical Trials of AKL-T01, A Novel Digital Therapeutic for Inattentive Symptoms in Children and Adolescents with ADHD.
Savarese A, Maple AM, Stamatis CA, et al. · CNS Spectr · 2024
- STARS Adjunct Trial: Evidence for the Effectiveness of a Digital Therapeutic as Adjunct to Treatment With Medication in Pediatric ADHD.
Maple A, Palko L, Cañadas E, et al. · CNS Spectr · 2023
Other devices of this type
Also filed under product code QFT.
- PrismiraLumos Labs, Inc. · 510(k) 2025
- EndeavorOTCAkili Interactive Labs, Inc. · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.